{"id":829263,"date":"2025-03-25T06:05:41","date_gmt":"2025-03-25T10:05:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update\/"},"modified":"2025-03-25T06:05:41","modified_gmt":"2025-03-25T10:05:41","slug":"x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update\/","title":{"rendered":"X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites;\u00a0<\/em>
\n full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026<\/em>\n <\/p>\n

\n 4WARD trial protocol refined, increasing confidence in successful outcome <\/em>\n <\/p>\n

\n 2024 XOLREMDI\u00ae net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through<\/em>\n <\/p>\n

\n Conference call and webcast today at 8:30 am ET<\/em>\n <\/p>\n

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals<\/strong><\/a> (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted key 2024 and recent events and expected upcoming milestones.<\/p>\n

\u201cAs expected, 2024 was a transformative year for the company and our momentum has continued into 2025,\u201d said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. \u201cWith the U.S. approval and launch of our first product, XOLREMDI\u00ae (mavorixafor) in WHIM syndrome, we are now a fully integrated company advancing our mission to serve those with rare immunodeficiencies and few treatment options. As we await word from the EU regulatory authority on the potential approval of mavorixafor for WHIM in that region, we\u2019ve continued to expand our potential reach to the global WHIM community through our recently completed commercialization partnerships in the EU, Australia, New Zealand, and the Middle East and North Africa (MENA) territories.\u201d<\/p>\n

Dr. Ragan continued: \u201cIn addition, we continue to make meaningful progress in our efforts to develop mavorixafor for the larger immunodeficiency population with chronic neutropenia (CN). Following positive results from our Phase 2 trial of mavorixafor in certain CN populations, we are currently conducting a global, pivotal Phase 3 trial in CN. With a large number of sites now activated and global screening ongoing, we expect full trial enrollment in the third or fourth quarter of this year and top-line trial data in the second half of 2026.\u201d<\/p>\n

Dr. Ragan concluded: \u201cMarket research and patient testimonials continue to strengthen our belief that there remains significant untapped potential for XOLREMDI for the U.S. and possibly global WHIM patient populations. We are equally confident in mavorixafor\u2019s future potential to address unmet needs in the global CN community.\u201d<\/p>\n

\n Key 2024 and Recent Corporate Highlights<\/strong>\n <\/p>\n

\n
\n Commercializing XOLREMDI\u00ae (mavorixafor) in WHIM Syndrome, a Rare Primary Immunodeficiency<\/em>
\n <\/strong>\n <\/p>\n